Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its CEO as the company advances its multiple sclerosis treatment...